Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunshine Biopharma has entered into an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University, to develop Sunshine's lead compound - Adva-27a, for the treatment of breast and prostate cancer.
Subscribe to our email newsletter
Adva-27a is a small molecule inhibitor of Topoisomerase II, an enzyme found in abundance in multi-drug resistant breast cancer as well as in other types of aggressive cancer.
Under the agreement, both the parties will conduct necessary research and development to accelerate Adva-27a through various stages of preclinical development and Phase I clinical trials for breast cancer and prostate cancer.
The agreement will be for a period of three years and will be renewed automatically for additional one year until the project is completed.
Sunshine president and CEO Steve Slilaty said the company is very excited to sign the agreement with Binghamton University.
"We anticipate completion by the first half of 2012 and if things go as we expect, we anticipate Adva-27a to be available for compassionate-use by the end of the trial," Slilaty said.